Page last updated: 2024-09-04

vatalanib and orantinib

vatalanib has been researched along with orantinib in 2 studies

Compound Research Comparison

Studies
(vatalanib)
Trials
(vatalanib)
Recent Studies (post-2010)
(vatalanib)
Studies
(orantinib)
Trials
(orantinib)
Recent Studies (post-2010) (orantinib)
2764298807
27642981101936

Protein Interaction Comparison

ProteinTaxonomyvatalanib (IC50)orantinib (IC50)
Epidermal growth factor receptorHomo sapiens (human)2.186
Platelet-derived growth factor receptor betaMus musculus (house mouse)3.6
Platelet-derived growth factor receptor betaHomo sapiens (human)1.126
Fibroblast growth factor receptor 1Homo sapiens (human)3.003
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.028
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)3.6
Vascular endothelial growth factor receptor 2Homo sapiens (human)1.8986
Aurora kinase BHomo sapiens (human)0.041
Aurora kinase CHomo sapiens (human)0.21

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

2 other study(ies) available for vatalanib and orantinib

ArticleYear
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017